Susan C. Weil

1.8k total citations
53 papers, 1.4k citations indexed

About

Susan C. Weil is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Susan C. Weil has authored 53 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Hematology. Recurrent topics in Susan C. Weil's work include Acute Myeloid Leukemia Research (11 papers), Ovarian cancer diagnosis and treatment (11 papers) and Cancer Research and Treatments (7 papers). Susan C. Weil is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Ovarian cancer diagnosis and treatment (11 papers) and Cancer Research and Treatments (7 papers). Susan C. Weil collaborates with scholars based in United States, United Kingdom and Netherlands. Susan C. Weil's co-authors include Charles Schweizer, Martin D. Phillips, Deborah K. Armstrong, P S Rudland, A. R. Hunter, Raffit Hassan, Robert L. Coleman, Ira Pastan, Steven J. Cohen and Daniel A. Laheru and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Susan C. Weil

51 papers receiving 1.4k citations

Peers

Susan C. Weil

ONCOL

IMMUN

PRM

Juan J. Roman United States

Alberto Gallardo Spain

Martha Hayden-Ledbetter United States

Cinda M. Boyer United States

Vanessa Chisholm United States

Elisabetta Bandiera Italy

S A Cannistra United States

Kristen A. Atkins United States

Lynne Krummen United States

Deyin Xing United States

Juan J. Roman United States

Susan C. Weil

728 ×1.4

ONCOL

568 ×1.2

599 ×1.9

IMMUN

214 ×0.8

154 ×0.6

PRM

Citations per year, relative to Susan C. Weil Susan C. Weil (= 1×) peers Juan J. Roman

Countries citing papers authored by Susan C. Weil

Since Specialization

Citations

This map shows the geographic impact of Susan C. Weil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan C. Weil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan C. Weil more than expected).

Fields of papers citing papers by Susan C. Weil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan C. Weil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan C. Weil. The network helps show where Susan C. Weil may publish in the future.

Co-authorship network of co-authors of Susan C. Weil

This figure shows the co-authorship network connecting the top 25 collaborators of Susan C. Weil. A scholar is included among the top collaborators of Susan C. Weil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan C. Weil. Susan C. Weil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klein, Nina, et al.. (2019). Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PLoS ONE. 14(4). e0215093–e0215093. 73 indexed citations

D’Angelo, Sandra P., Omid Hamid, Ahmad A. Tarhini, et al.. (2017). A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs. 36(1). 103–113. 21 indexed citations

Wang, Wenquan, Elizabeth B. Somers, J. Bradford Kline, et al.. (2017). FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. Cytogenetic and Genome Research. 152(4). 169–179. 16 indexed citations

O’Shannessy, Daniel J., Charles Schweizer, Wenquan Wang, et al.. (2017). Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics. 109(3-4). 251–257. 15 indexed citations

O’Shannessy, Daniel J., Charles Schweizer, Wenquan Wang, et al.. (2016). Analysis of molecular and protein signatures on farletuzumab pharmacokinetics from a phase 3 ovarian cancer study.. Journal of Clinical Oncology. 34(15_suppl). e14508–e14508. 1 indexed citations

Kim, Kenneth H., Danijela Jelovac, Deborah K. Armstrong, et al.. (2015). Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Gynecologic Oncology. 140(2). 210–214. 29 indexed citations

Armstrong, Deborah K., et al.. (2013). Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecologic Oncology. 129(3). 452–458. 114 indexed citations

Elit, L., Jason Konner, Martin Buck, et al.. (2010). A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). TPS255–TPS255. 5 indexed citations

Hassan, Raffit, Charles Schweizer, Barbara Schüler, et al.. (2009). Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer. 68(3). 455–459. 61 indexed citations

10.

Chen, Xiaowei, Joellen Weaver, Betsy Bove, et al.. (2008). Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Human Molecular Genetics. 17(9). 1336–1348. 52 indexed citations

11.

Laheru, Daniel A., Steven J. Cohen, Julie R. Brahmer, et al.. (2008). A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer. Journal of Clinical Oncology. 26(15_suppl). 3578–3578. 3 indexed citations

12.

Bell‐McGuinn, Katherine M., Jason Konner, Neeta Pandit‐Taskar, et al.. (2007). A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer. Journal of Clinical Oncology. 25(18_suppl). 5553–5553. 1 indexed citations

13.

Gibas, Zenon, et al.. (1994). Deletion of chromosome arm 1p in a merkel cell carcinoma (MCC). Genes Chromosomes and Cancer. 9(3). 216–220. 17 indexed citations

14.

Hirata, Roli K., et al.. (1993). Expression of granule protein mRNAs in acute promyelocytic leukemia.. PubMed. 7(4). 225–38. 20 indexed citations

15.

Anastasi, John, Mark J. Pettenati, Michelle M. Le Beau, Hau C. Kwaan, & Susan C. Weil. (1988). Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: Cytogenetic analysis reveals two distinct abnormal clones. American Journal of Hematology. 29(1). 33–37. 17 indexed citations

16.

Miki, T., et al.. (1988). An MPO cDNA clone identifies an RFLP with PstI. Nucleic Acids Research. 16(4). 1649–1649. 4 indexed citations

17.

Weil, Susan C., et al.. (1987). A Hybrid Eosinophilic–Basophilic Granulocyte in Chronic Granulocytic Leukemia. American Journal of Clinical Pathology. 87(1). 66–70. 27 indexed citations

18.

Weil, Susan C., et al.. (1986). A Variant Myelodysplastic Syndrome with Multilineage Pelgeroid Chromatin. American Journal of Clinical Pathology. 85(2). 176–179. 7 indexed citations

19.

Weil, Susan C., et al.. (1985). Melanin Inclusions in the Peripheral Blood Leukocytes of a Patient with Malignant Melanoma. American Journal of Clinical Pathology. 84(5). 679–681. 1 indexed citations

20.

Gusella, James F., Asterios S. Tsiftsoglou, Vladimir Volloch, et al.. (1982). Dissociation of hemoglobin accumulation and commitment during murine erythroleukemia cell differentiation by treatment with imidazole. Journal of Cellular Physiology. 113(1). 179–185. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact